Evidence map›Paper›PMID 32661502›Full record

ArticleJournal of cancer metastasis and treatment2019

Novel Immunotherapeutic Approaches in Head and Neck Cancer.

M E Heft Neal, C T Haring, J E Mann, J C Brenner, M E Spector, P L Swiecicki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer metastasis and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Immunotherapy: The future of cancer treatment.Journal of oral and maxillofacial pathology : JOMFP
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

M E Heft NealDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, MI.
C T HaringDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, MI.
J E MannDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, MI.
J C BrennerDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, MI.
M E SpectorDepartment of Otolaryngology Head and Neck Surgery, University of Michigan, Ann Arbor, MI.
P L SwiecickiDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, Michigan.

Funding

Advanced Research Training in OtolaryngologyT32DC005356 · NIDCD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CORFAS, GABRIEL · 2002 to 2021
$3.5M
Advancing Mechanistic Concepts of FGFR1-Regulated Adaptive PDL1 Expression in HNSCCF31DE027600 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MANN, JACQUELINE · 2017 to 2019
$99k
NIDCD NIH HHS T32 DC005356NIDCR NIH HHS F31 DE027600
6 · The paper itself

Abstract

Unresectable recurrent or metastatic head and neck cancer is an incurable disease with survival of approximately 12 months. Head and neck tumors exhibit numerous derangements in the tumor microenvironment that aid in immune evasion and may serve as targets for future therapies. Pembrolizumab is now approved as a first line therapy. Despite the promise of currently approved immunotherapies there continues to be low response rates and additional strategies are needed. Here, alterations in the immune microenvironment and current therapeutic strategies are reviewed with a focus on novel immunologic approaches.

Identifiers

PMID32661502
PMCPMC7357897

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.